Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
Study to understand how incretin mimetics affect cancer risk and attract experts to investigate these mechanisms, aiming to differentiate impacts on cancer risk from other health outcomes like weight loss or diabetes.
Funder: National Institutes of Health
Due Dates: June 5, 2025 (New) | July 5, 2025 (Renewal/Resubmission/Revision) | October 5, 2025 (New) | November 5, 2025 (Renewal/Resubmission/Revision) | February 5, 2026 (New) | March 5, 2026 (Renewal/Resubmission/Revision) | June 5, 2026 (New) | July 5, 2026 (Renewal/Resubmission/Revision) | October 5, 2026 (New) | November 5, 2026 (Renewal/Resubmission/Revision)
Funding Amounts: No budget cap; budgets must reflect actual project needs. Maximum project period: 5 years.
Summary: Supports research on the mechanisms by which incretin mimetics (GLP-1, GIP-1, or dual agonists) impact cancer risk, with clinical trial option.
Key Information: Non-domestic (non-U.S.) entities are eligible; animal or human studies must include mechanistic endpoints, not just epidemiology.
Description
This opportunity, issued by the National Cancer Institute (NCI) at NIH, invites investigator-initiated R01 applications to study the mechanisms by which incretin mimetics—specifically GLP-1, GIP-1, or dual GLP-1/GIP-1 receptor agonists—impact cancer risk. The focus is on understanding the biological pathways and effects of these agents, which are widely used for type 2 diabetes and obesity, and have shown both potential cancer risk and protective effects in preliminary studies. The program aims to attract researchers with expertise in the biology of incretin mimetics to address cancer risk, rather than short-term outcomes like weight loss or glycemic control.
Both preclinical (animal) and patient-based (human) mechanistic studies are supported. Clinical trials are optional. Projects must focus on mechanistic endpoints (e.g., molecular, cellular, or biomarker changes linked to cancer risk), not solely on epidemiological outcomes.
